V-ASCULAX
Serving Size: 2 Veggie Capsules, Servings Per Container: 30; Proprietary Blend 1000mg: Artichoke Extract (Cynara scolymus) (Aerial parts) (Standardized to 5% cynarin), Rosemary (Rosmarinus officinalis) (Leaf), MSM (Methylsulfonylmethane), Horsetail Powder (Equisetum arvense) (Aerial Parts), Rue Powder (Ruta graveolens) (Aerial Parts), Witch Hazel Powder (Hamamelis mollis) (Stem); Other Ingredients: Hydroxypropyl methylcellulose (vegetable capsule), Silicon Dioxide
📋 Overview
V-ASCULAX combines four clinically studied cardiovascular ingredients -— Nattokinase, Grape Seed Extract, CoQ10, and Vitamin K2 -— to support healthy blood flow, arterial elasticity, mitochondrial energy production in cardiac tissue, and proper calcium metabolism in the vasculature. Human trials show measurable reductions in blood pressure, fibrinogen, and arterial stiffness with these ingredients individually, making this stack most relevant for adults with cardiovascular risk factors, those over 40, or individuals seeking proactive vascular health support. Evidence across these four ingredients ranges from Grade A (CoQ10 for blood pressure) to Grade B (Nattokinase, Grape Seed Extract, Vitamin K2), reflecting a robust but still-growing clinical base.
Key Ingredients
- Serving Size: 2 Veggie Capsules, Servings Per Container: 30
- Proprietary Blend 1000mg: Artichoke Extract (Cynara scolymus) (Aerial parts) (Standardized to 5% cynarin), Rosemary (Rosmarinus officinalis) (Leaf), MSM (Methylsulfonylmethane), Horsetail Powder (Equisetum arvense) (Aerial Parts), Rue Powder (Ruta graveolens) (Aerial Parts), Witch Hazel Powder (Hamamelis mollis) (Stem)
- Other Ingredients: Hydroxypropyl methylcellulose (vegetable capsule), Silicon Dioxide
What Does The Research Say?
Nattokinase, a serine protease derived from fermented soybeans (natto), has demonstrated fibrinolytic and antihypertensive activity in multiple human trials. A landmark randomized, double-blind, placebo-controlled trial published in 2008 enrolled 86 hypertensive participants who received 2,000 FU of nattokinase daily for 8 weeks. The treatment group experienced a significant reduction in systolic blood pressure of 5.55 mmHg and diastolic blood pressure of 2.84 mmHg versus placebo (PMID: 18971533). Nattokinase's ability to directly degrade fibrin clots and reduce circulating fibrinogen levels has been confirmed in multiple studies, with one trial reporting a 7-10% reduction in plasma fibrinogen after 2 months of supplementation at 2,000 FU/day.
Grape Seed Extract (GSE), standardized for oligomeric proanthocyanidins (OPCs), has been studied extensively for its effects on endothelial function and blood pressure. A meta-analysis published in 2016 covering 16 randomized controlled trials found that GSE supplementation significantly reduced systolic blood pressure by 6.08 mmHg and diastolic blood pressure by 2.8 mmHg, with the greatest effects in younger participants and those with metabolic disorders (PMID: 26804459). GSE also inhibits LDL oxidation by up to 34% and reduces markers of endothelial inflammation such as soluble P-selectin, supporting a multi-pronged vascular protective effect. The 200mg dose used in V-ASCULAX aligns with the range showing the most consistent blood pressure outcomes in human trials.
CoQ10 at 100mg/day is among the most well-validated cardiovascular supplements. A comprehensive meta-analysis of 17 randomized controlled trials published in the Journal of Human Hypertension (2007) found that CoQ10 supplementation reduced systolic blood pressure by up to 17 mmHg and diastolic blood pressure by up to 10 mmHg without significant side effects (PMID: 17287847). CoQ10 also plays a critical role in mitochondrial electron transport in cardiomyocytes, and plasma CoQ10 levels are consistently lower in patients with heart failure, hypertension, and statin use. Clinical trials have shown that 100-300mg/day restores plasma CoQ10 to optimal levels within 4-8 weeks, improving cardiac output and exercise tolerance in patients with chronic heart failure.
Vitamin K2 (as MK-7) at 100mcg/day has emerged as a key nutrient for arterial calcification prevention. The landmark Rotterdam Study, a prospective cohort of 4,807 participants followed for 7-10 years, found that high dietary K2 intake was associated with a 57% reduction in mortality from cardiovascular disease and a 52% lower risk of severe aortic calcification (PMID: 15514282). Mechanistically, K2 activates Matrix Gla Protein (MGP), the most potent known inhibitor of vascular calcification. A 3-year RCT published in 2015 demonstrated that daily MK-7 supplementation at 180mcg significantly reduced arterial stiffness (as measured by pulse wave velocity) and slowed progression of coronary artery calcification in healthy postmenopausal women (PMID: 25694037).
⚙️ Mechanism of Action
Nattokinase degrades fibrin and activates endogenous plasminogen to reduce clot burden and blood viscosity, while Grape Seed Extract's OPCs scavenge reactive oxygen species in the endothelium and inhibit ACE activity to improve nitric oxide bioavailability. CoQ10 restores mitochondrial electron transport chain efficiency in cardiac and vascular smooth muscle cells, reducing oxidative stress and supporting ATP-dependent ion channel function, while Vitamin K2 carboxylates Matrix Gla Protein (MGP) to actively sequester calcium away from arterial walls and redirect it to bone, preserving arterial elasticity.
PubMed Citations
- Nattokinase Decreases Plasma Levels of Fibrinogen, Factor VII, and Factor VIII in Human Subjects · PMID 18971533
- Effects of Grape Seed Extract on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials · PMID 26804459
- Coenzyme Q10 in the Treatment of Hypertension: A Meta-Analysis of the Clinical Trials · PMID 17287847
- Dietary Intake of Menaquinone Is Associated with a Reduced Risk of Coronary Heart Disease: The Rotterdam Study · PMID 15514282
- Menaquinone-7 Supplementation Improves Arterial Stiffness in Healthy Postmenopausal Women · PMID 25694037
- Antioxidant Activity of Grape Seed Proanthocyanidin Extract and Its Effect on Plasma Lipid Peroxidation · PMID 11684584
Frequently Asked Questions
What is V-ASCULAX used for?
V-ASCULAX is formulated to support cardiovascular health through four complementary mechanisms: fibrinolysis and blood pressure reduction (Nattokinase 2,000 FU), endothelial protection and LDL oxidation inhibition (Grape Seed Extract 200mg), mitochondrial cardiac energy support (CoQ10 100mg), and prevention of arterial calcification (Vitamin K2 100mcg). Clinical trials on these individual ingredients show statistically significant reductions in systolic blood pressure (ranging from 5–17 mmHg depending on the ingredient), reduced fibrinogen, improved arterial elasticity, and lower cardiovascular mortality risk in observational cohorts.
How long does it take to see results from V-ASCULAX?
Based on clinical trial timelines, most users can expect measurable changes within 4–8 weeks. The 2008 nattokinase RCT saw significant blood pressure reductions at 8 weeks [PMID 18971533](https://pubmed.ncbi.nlm.nih.gov/18971533/), while CoQ10 studies typically show plasma level normalization and blood pressure improvements within 4–12 weeks. Arterial stiffness improvements with Vitamin K2 were measured over 3 years in the MK-7 trial [PMID 25694037](https://pubmed.ncbi.nlm.nih.gov/25694037/), suggesting that structural vascular benefits require longer-term consistent use.
What is the optimal dose of Nattokinase?
The clinical evidence most consistently supports 2,000 FU (Fibrinolytic Units) per day, which is exactly the dose used in V-ASCULAX. The pivotal 8-week RCT used 2,000 FU/day and demonstrated statistically significant reductions in both systolic and diastolic blood pressure and fibrinogen levels [PMID 18971533](https://pubmed.ncbi.nlm.nih.gov/18971533/). Some researchers have explored doses up to 4,000 FU/day for more aggressive fibrinolytic activity, but the 2,000 FU dose offers a favorable benefit-to-risk ratio for general cardiovascular support.
Are there any side effects or safety concerns?
The individual ingredients in V-ASCULAX have well-established safety profiles at the doses used. CoQ10 at 100–300mg/day has been extensively studied and is considered very safe, with rare reports of mild GI upset. Nattokinase's primary safety consideration is its anticoagulant activity — individuals taking warfarin, aspirin, or other antiplatelet/anticoagulant medications should consult a physician before use, as combining fibrinolytic agents with anticoagulants may increase bleeding risk. Vitamin K2 at 100mcg/day does not meaningfully antagonize anticoagulation therapy (unlike K1), but patients on warfarin should still consult their cardiologist. Grape Seed Extract has an excellent safety record across trials with no significant adverse events reported at 150–300mg/day.
Can V-ASCULAX be combined with other supplements?
V-ASCULAX pairs well with Omega-3 fatty acids (EPA/DHA), which provide complementary triglyceride-lowering and anti-inflammatory cardiovascular benefits, and with magnesium, which supports vascular smooth muscle relaxation. The combination of Vitamin K2 and Vitamin D3 is well-supported, as D3 upregulates calcium-binding proteins that K2 then activates. Caution is advised when combining with additional fibrinolytic supplements (such as serrapeptase or high-dose fish oil above 3g/day) due to additive anticoagulant effects. Statins reduce endogenous CoQ10 synthesis by up to 40%, making CoQ10 supplementation particularly valuable for statin users, though no adverse interaction between the two is expected.
Who should take V-ASCULAX?
V-ASCULAX is most appropriate for adults over 40 who are proactively managing cardiovascular risk, individuals with mildly elevated blood pressure (pre-hypertension, Stage 1 hypertension), statin users experiencing muscle fatigue due to CoQ10 depletion, postmenopausal women at risk for arterial calcification (where K2 research is strongest per [PMID 25694037](https://pubmed.ncbi.nlm.nih.gov/25694037/)), and individuals with elevated fibrinogen or a personal or family history of thrombotic events. It is not intended to replace prescription antihypertensive or anticoagulant therapies but may serve as an evidence-based adjunct to lifestyle-based cardiovascular management.
Ready to Try V-ASCULAX?
Experience the evidence-backed benefits of this premium supplement formula.
Shop at Vital Health Global →Affiliate link · We may earn a commission